Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

NCT02517502 is registered in ClinicalTrials.gov with Carol Fabian, MD as lead sponsor.

NCT NCT02517502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02517502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
Lead sponsor
Carol Fabian, MD
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2015
Completion date
May 3, 2019
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive dysfunction